Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06685692 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT06685692 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 4 participants.
The verdict
NCT06685692, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
Interventions
- DRUG ADX-629
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-11-04 |
| Est. Completion | 2025-06-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06685692
The ClinicalTrials.gov registry entry for NCT06685692 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADX-629 is the first listed.
NCT06685692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06685692 about?
NCT06685692 is a clinical study titled "A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)". A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Moderate Alcohol Associated Hepatitis (Part 1)
What is the current status of trial NCT06685692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-11-04. Estimated completion is 2025-06-18.
What interventions are being tested in trial NCT06685692?
The interventions under investigation include: ADX-629 (DRUG).
Who is sponsoring clinical trial NCT06685692?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.